本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：301601 证券简称：惠通科技 公告编号：2025-060 扬州惠通科技股份有限公司 关于聘任公司副总经理的公告 2 扬州惠通科技股份有限公司（以下简称"公司"）于 2025 年 9 月 25 日召开 第四届董事会第三次会议，审议通过了《关于聘任公司副总经理的议案》，经公 司总经理提名，第四届董事会提名委员会审核通过，董事会同意聘任李清先生为 公司副总经理（简历后附），任期自本次董事会审议通过之日起至第四届董事会 任期届满之日止。 李清先生符合相关法律法规、规范性文件规定的高级管理人员任职资格。 特此公告。 扬州惠通科技股份有限公司董事会 2025 年 9 月 26 日 1 附件： 李清先生，男，1976 年 11 月出生，中国国籍，无境外永久居留权，中专学历。1996 年 7 月至 1998 年 12 月，就职于扬州惠通聚酯技术有限公司；1998 年 12 月至今，历任惠通 有限、惠通科技采购专员、采购主办、采购经理。 截至本公告披露日，李清先生通过扬州惠誉管理咨询合伙企业（有限合伙）间接持有公 司 ...

证券代码：301601 证券简称：惠通科技 公告编号：2025-061 扬州惠通科技股份有限公司 第四届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 扬州惠通科技股份有限公司（以下简称"公司"）第四届董事会第三次会议 通知已于 2025 年 9 月 19 日通过微信、邮件等通讯方式送达。会议于 2025 年 9 月 25 日以现场结合通讯的方式在公司会议室召开，本次会议应出席董事 12 人， 实际出席董事 11 人，委托出席董事 1 人，其中范以宁先生、陈曦女士、周围先 生、魏高富先生、景辽宁先生以通讯方式参加，董事钟明先生因出差无法出席本 次董事会，委托董事张建纲先生代为出席并表决。会议由董事长严旭明先生召集 并主持，公司部分高级管理人员列席了会议。本次会议的召集、召开和表决程序 符合《中华人民共和国公司法》等法律法规、规范性文件和《公司章程》的有关 规定，会议合法、有效。 二、董事会会议审议情况 （一）审议通过《关于聘任公司副总经理的议案》 经公司总经理提名，第四届董事会提名委员会审核通过，董事会同意聘任 ...

Group 1 - The core viewpoint of the news highlights the recent trading performance and financial metrics of Huitong Technology, indicating a slight increase in stock price and specific financing activities on September 24 [1] - On September 24, Huitong Technology's stock rose by 1.29%, with a trading volume of 34.97 million yuan. The financing buy-in amounted to 5.03 million yuan, while the financing repayment was 4.95 million yuan, resulting in a net financing buy of 0.08 million yuan [1] - As of September 24, the total margin balance for Huitong Technology was 63.63 million yuan, representing 6.24% of its circulating market value [1] Group 2 - As of June 30, the number of shareholders for Huitong Technology was 19,200, a decrease of 11.75% from the previous period. The average circulating shares per person increased by 13.31% to 1,564 shares [2] - For the first half of 2025, Huitong Technology reported operating revenue of 277 million yuan, a year-on-year decrease of 37.49%. The net profit attributable to the parent company was 16.37 million yuan, down 80.24% year-on-year [2] Group 3 - Huitong Technology has cumulatively distributed dividends amounting to 25.29 million yuan since its A-share listing [3]

Investment Rating - The industry investment rating is "Positive" (看好) indicating that the industry is expected to outperform the overall market [2][10]. Core Insights - The release of Tencent's Hunyuan 3D 3.0 model significantly enhances modeling precision by three times, achieving a geometric resolution of 1536³ and supporting ultra-high-definition modeling with 3.6 billion voxels [2][4]. - The model introduces a novel 3D-DiT hierarchical sculpting approach, improving the understanding and restoration of invisible areas, thus addressing the challenges of generating complex structures and fine details [4]. - The model has been optimized for character generation, enhancing the realism and aesthetic appeal of 3D models, particularly for creating lifelike figurines [4]. - Tencent's Hunyuan model has accelerated iterations, releasing over 30 new models and embracing open-source, with the 3D model community achieving over 2.6 million downloads [4]. - Several companies have integrated Tencent's models, lowering the barriers for 3D modeling and accelerating the penetration of consumer-grade 3D printing [4]. Summary by Sections Industry Overview - The report highlights the rapid advancement in consumer-grade 3D printing technology, driven by Tencent's innovations [2][4]. Key Players in the Industry - Core industry players include: 1. Hardware: Anker Innovation, Tuo Zhu Technology, and others 2. Components: Jietu, Ruike Laser, and others 3. 3D Scanners: Sikan Technology, Obi Zhongguang 4. Materials: Haizheng Biomaterials, Huitong Technology, and others [4]. Valuation Table - The valuation table provides insights into the market capitalization and projected net profits for key companies in the industry, indicating a positive outlook for growth in the coming years [5].

Group 1 - China Shenhua reported coal sales of 37.5 million tons in August, a year-on-year decrease of 3.1%, with total sales for the first eight months at 280 million tons, down 9.2% year-on-year [1] - China Shenhua, established in November 2004, focuses on coal and electricity production and sales, as well as transportation and coal-to-olefins [1] - Huaren Shuanghe's subsidiary received a drug registration certificate for a new injection used in treating non-ST elevation acute coronary syndrome [1] - Huaren Shuanghe, founded in May 1997, operates in chronic disease management, specialty business, and infusion business [1] Group 2 - New Wufeng's subsidiary signed a property transaction contract for a 60% equity transfer at a price of 9.7 million yuan [1] - New Wufeng, established in June 2001, specializes in pig farming, meat sales, and feed processing [2] - Yaoshi Technology announced that its convertible bonds will stop conversion after September 17, with remaining bonds to be redeemed at 100.62 yuan per bond [3] - Yaoshi Technology, founded in December 2006, focuses on drug molecular building blocks and related services [3] Group 3 - Newhua Co. announced a board member's plan to reduce holdings by up to 75,200 shares, representing 0.039% of total shares [4] - Newhua Co., established in September 1997, specializes in fine chemical products [4] - Hefei Construction's subsidiary signed a land use rights transfer contract for residential land with a total price of 12.24 billion yuan [6] - Hefei Construction, founded in September 1999, is involved in real estate development and property management [6] Group 4 - Guoyao Modern's subsidiary received a drug registration certificate for an injection used in anesthesia and emergency treatment [7] - Guoyao Modern, established in November 1996, focuses on pharmaceutical product development and sales [7] - Maohua Shihua announced the resignation of its deputy general manager [8] - Maohua Shihua, founded in October 1988, specializes in petrochemical products [9] Group 5 - Zhejiang Xineng applied for enforcement of a civil mediation agreement, seeking 170 million yuan from a group for breach of contract [10] - Zhejiang Xineng, established in December 1991, focuses on renewable energy projects [10] - Zejing Pharmaceutical announced the initiation of key clinical trials for a new drug targeting DLL3 [11] - Zejing Pharmaceutical, founded in March 2009, specializes in the development and production of new chemical and biological drugs [12] Group 6 - Huayi Technology's deputy general manager resigned due to personal work arrangements [13] - Huayi Technology, established in December 1998, focuses on high polymer materials and equipment manufacturing [13] - Luxiao Technology's subsidiary signed a strategic cooperation agreement with a leading cross-border e-commerce company [14] - Luxiao Technology, founded in May 1989, operates in various sectors including photovoltaic power generation [14] Group 7 - Aoxiang Pharmaceutical's subsidiary received a drug registration certificate for a new cancer treatment [15] - Aoxiang Pharmaceutical, established in April 2010, focuses on the development and production of pharmaceutical products [15] - Baiyunshan's pharmaceutical factory received approval for five drug supplement applications [16] - Baiyunshan, founded in September 1997, specializes in the research and production of various pharmaceutical products [16] Group 8 - Renfu Pharmaceutical's subsidiaries received drug registration certificates for two new products [17] - Renfu Pharmaceutical, established in March 1993, focuses on drug research and production [18] - China Shipbuilding Technology signed a significant contract for green methanol sales, potentially worth up to 1.2 billion dollars [19] - China Shipbuilding Technology, founded in May 1997, specializes in wind and solar resource development [19] Group 9 - Haohua Technology received a project designation from a global automotive brand for its ADAS system [20] - Haohua Technology, established in January 2010, focuses on intelligent driving perception systems [20] - Hendi Pharmaceutical received approval for a new raw material drug [21] - Hendi Pharmaceutical, founded in December 1995, specializes in chemical raw materials and formulations [22] Group 10 - JX Communication's subsidiary received a temporary use permit for an air traffic communication system [23] - JX Communication, established in January 1995, focuses on communication technology applications [23] - Longyuan Technology's deputy general manager resigned due to work reasons [24] - Longyuan Technology, founded in December 1998, specializes in energy-saving and environmental protection [25] Group 11 - Jiuqiang Bio received a medical device registration for a gastrin-17 assay kit [26] - Jiuqiang Bio, established in January 2001, focuses on in vitro diagnostic testing platforms [26] - Rifei Co. received approval for a stock issuance to specific investors [27] - Rifei Co., founded in December 2009, specializes in special equipment cables and other electrical devices [27] Group 12 - Huayi Media received a subsidy for a micro-short drama project [28] - Huayi Media, established in August 1998, focuses on film and game content investment [28] - Huilong Pharmaceutical's subsidiary received overseas marketing approvals for multiple products [29] - Huilong Pharmaceutical, founded in October 2010, specializes in innovative and high-quality generic drugs [29] Group 13 - Junsheng Electronics' subsidiary received project designations from two major automotive brands [30] - Junsheng Electronics, established in August 1992, focuses on automotive parts [30] - Silek signed an investment cooperation agreement for a new energy project [31] - Silek, founded in January 2004, specializes in metal packaging equipment [31] Group 14 - ST Huhuwa received drug registration certificates for two new products [32] - ST Huhuwa, established in June 2005, focuses on drug research and production [32] - Canray Technology announced a share buyback plan of 20 to 40 million yuan [33] - Canray Technology, founded in September 2005, specializes in integrated circuits [33] Group 15 - Qilu Bank's directors plan to collectively increase their holdings by at least 3.5 million yuan [34] - Qilu Bank, established in June 1996, focuses on corporate and personal banking services [34] - China Overseas Land reported a significant decrease in contract sales in August [35] - China Overseas Land, founded in September 1997, specializes in tourism and real estate [35] Group 16 - Longjian Co. plans to acquire 100% of Guangdong Zhimao's equity for 40,000 yuan [36] - Longjian Co., established in January 1993, focuses on infrastructure construction [36] - Lichong Group's subsidiary received project designations from a luxury car brand [37] - Lichong Group, founded in July 1998, specializes in aluminum alloy products [37] Group 17 - Kanglong Huacheng's subsidiary passed an FDA inspection [38] - Kanglong Huacheng, established in July 2004, focuses on integrated drug research and development services [38] - Kangtai Bio received a drug registration certificate for a new polio vaccine [39] - Kangtai Bio, founded in September 1992, specializes in vaccine development and production [39] Group 18 - Baiyunshan's pharmaceutical factory's drug entered a key clinical trial phase [40] - Baiyunshan, established in September 1997, focuses on various pharmaceutical products [40] - Zhongyuan Home's chairman plans to reduce holdings by up to 3% [41] - Zhongyuan Home, founded in November 2001, specializes in furniture production [41] Group 19 - Shangluo Electronics plans to acquire 88.79% of Ligon Technology's equity for 709 million yuan [42] - Shangluo Electronics, established in August 1999, focuses on electronic components [42] - Shangluo Electronics also plans to issue convertible bonds to raise 1 billion yuan [43] - Shangluo Electronics, founded in August 1999, specializes in electronic products for various applications [43] Group 20 - HNA Holdings reported a 3.38% increase in passenger capacity in August [44] - HNA Holdings, established in December 1995, focuses on air transportation services [44] - Yipin Hong's subsidiary received a drug registration certificate for a new product [45] - Yipin Hong, founded in February 2002, specializes in pharmaceutical production [45] Group 21 - Haishi Ke's innovative drug received approval for a new indication [46] - Haishi Ke, established in August 2005, focuses on new drug development [46] - Huaxia Airlines plans to repurchase shares worth 80 to 160 million yuan [47] - Huaxia Airlines, founded in April 2006, specializes in air transportation services [47] Group 22 - Jingchen Co. plans to acquire 100% of Xinchip Microelectronics for 316 million yuan [48] - Jingchen Co., established in July 2003, focuses on semiconductor design [48] - Zhongxin Heavy Industry was recognized as an excellent smart factory by the Ministry of Industry and Information Technology [49] - Zhongxin Heavy Industry, founded in January 2008, specializes in large equipment and technology solutions [49]

证券代码：301601 证券简称：惠通科技 公告编号：2025-059 截至本公告披露日，时虎先生未直接持有公司股票，通过扬州惠誉管理咨询 合伙企业（有限合伙）间接持有公司 380,000 股，通过扬州惠金管理咨询合伙企 业（有限合伙）间接持有公司 320,000 股，通过申万宏源惠通科技员工参与创业 板战略配售 1 号集合资产管理计划间接持有公司 0.07%股份，合计间接持有公司 0.57%股份，时虎先生离职后将继续遵守股份变动相关法律、规范性文件的规定 及其在公司首次公开发行时所作出的相关承诺。 特此公告。 扬州惠通科技股份有限公司董事会 2025 年 9 月 17 日 关于副总经理辞职的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 扬州惠通科技股份有限公司（以下简称"公司"）董事会于近日收到公司副 总经理时虎先生的书面辞职报告，时虎先生因个人工作安排，申请辞去公司副总 经理职务，辞职后不再担任公司任何职务。时虎先生担任公司副总经理的原定任 期至公司第四届董事会任期届满之日止。 根据《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规 ...

证券代码：301601 证券简称：惠通科技 公告编号：2025-058 扬州惠通科技股份有限公司 关于使用部分闲置募集资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 扬州惠通科技股份有限公司（以下简称"公司"）于 2025 年 3 月 26 日召开第 三届董事会第十三次会议、第三届监事会第十三次会议，审议通过了《关于使用 部分闲置募集资金进行现金管理的议案》，同意公司在不影响募集资金投资项目 （以下简称"募投项目"）建设和公司正常经营的情况下，使用不超过人民币 2.7 亿元（含本数）的闲置募集资金进行现金管理。现金管理期限自公司第三届董事 会第十三次会议审议通过之日起 12 个月内有效，在上述额度和期限内，资金可 循环滚动使用，并授权公司管理层在上述额度和期限范围内行使投资决策权、签 署相关文件及办理其他相关事宜，公司财务部门具体办理相关事宜。公司本次使 用部分闲置募集资金进行现金管理事项在董事会的审批权限内，无需提交股东大 会审议。具体内容详见公司在巨潮资讯网（www.cninfo.com.cn）披露的《关于使 用部分闲置募集资金 ...

Core Viewpoint - The company reported a significant decline in revenue and net profit for the first half of 2025, primarily due to the timing of large project deliveries and a high base from the previous year [1] Financial Performance - The company achieved operating revenue of 277 million yuan, a year-on-year decrease of 37.5% [1] - The net profit attributable to shareholders was 16.37 million yuan, down 80.2% year-on-year [1] Project and Order Status - The company has a robust order reserve, with the amount of contractual obligations reaching 1.368 billion yuan, providing a foundation for future growth [1] - The equipment manufacturing business generated revenue of 190 million yuan, accounting for nearly 70% of total revenue, with a gross margin maintained above 30% [1] - The EPC (Engineering, Procurement, and Construction) business saw revenue of 60.06 million yuan, reflecting a year-on-year growth of 22.7%, indicating ongoing expansion in engineering services [1] Future Outlook - The company plans to focus on key areas such as nylon 66, biodegradable materials, and hydrogen peroxide in the second half of the year [1] - The strategy includes enhancing technical marketing and customer collaboration to drive order conversion and aim for a recovery in performance [1]

扬州惠通科技股份有限公司 证券代码：301601 证券简称：惠通科技 公告编号：2025-056 关于 2025 年半年度计提信用减值准备及资产减值准备的公告 三、本次计提信用减值准备及资产减值准备的确认标准及计提方法 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、本次计提信用减值准备及资产减值准备情况概述 为真实反映扬州惠通科技股份有限公司（以下简称"公司"）的财务状况、 资产价值及经营情况，本着谨慎性原则，根据《企业会计准则》及公司会计政策 的相关规定，公司对合并报表范围内截至 2025 年 6 月 30 日的各类资产进行了全 面清查和减值测试，并进行了充分的评估和分析，对其中存在减值迹象的资产相 应计提了减值损失。 根据《深圳证券交易所创业板股票上市规则》等相关法律法规以及《公司章 程》等相关规定，本次计提资产减值准备无需提交公司董事会或股东会审议。 二、本次计提信用减值准备及资产减值准备的范围和总金额 公 司 2025 年 半 年 度 对 相 关 资 产 计 提 信 用 及 资 产 减 值 准 备 总 额 为 20,345,469.37 元，详情 ...

法定代表人：张建纲 主管会计工作负责人 ：周建 会计机构负责人：周建 附件： 扬州惠通科技股份有限公司 2025年1-6月非经营性资金占用及其他关联资金往来情况汇总表 单位：人民币万元 | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公司的关联 | 上市公司核算的会计科 | 2025年期初占用资 | 2025年1-6月占用累计 | | 2025年1-6月占用资 | 2025年1-6月偿还累 | 2025年6月末占用资 | 占用形成原因 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 关系 | 目 | 金余额 | 发生金额（不含利息） | | 金的利息（如有） | 计发生金额 | 金余额 | | | | 控股股东、实际控制 | | | | | | | | | | | | | 人及其附属企业 | | | | | | | | | | | | | 小计 | | - | - | | | | | | | | | | 前控股股东、实际控 | | | | | | | | | | | | ...